Yarrow Bioscience, Inc. (VYNE) Company Overview

Yarrow Bioscience, Inc. also develops VYN202, a BD2-selective oral small molecule BET inhibitor in Phase. Review VYNE filings, fundamentals, valuation, and ownership on Finoriq.

Company Snapshot

VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions. The company's lead program is repibresib gel (VYN201), a topically administered small molecule pan-bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple and diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor in Phase 1b trial for the acute control and chronic management of immune-mediated inflammatory conditions. VYNE Therapeutics Inc. was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. The company was founded in 2003 and is based in Stewartsville, New Jersey.

Company: Yarrow Bioscience, Inc. (VYNE)
Ticker: VYNE
Market Cap: $929.4M
Latest Price: $27.84
Industry: Biotech & Pharma

Open insider transactions

Yarrow Bioscience, Inc. (VYNE) Current Valuation Metrics

Static valuation preview for Yarrow Bioscience, Inc. (VYNE). Market data retrieved 2026-07-09. Filing currency USD.

Metric	Value	Source
P/SMarket cap divided by latest TTM revenue.	39.3x	Revenue \| TTM FY 2025
Earnings YieldLatest TTM net income divided by market cap.	-118.2%	Net Income \| TTM FY 2025
Operating Cash Flow YieldLatest TTM operating cash flow divided by market cap.	-147.8%	Operating Cash Flow \| TTM FY 2025
Price / BookMarket cap divided by stockholders' equity.	0.91x	Stockholders' Equity \| Q1 2026

Live data loads in the app

This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.